Sep 2026· International Journal of Innovative Technologies in Social Science· 0 citations· 62 references
TL;DR
All treatment is becoming more personalized and increasingly guided by immunotherapy, molecular targets, and MRD, although resistance, immune toxicity, transplantation decisions, cost, and unequal access remain important barriers.
Abstract
Objectives: Acute lymphoblastic leukemia (ALL) treatment is changing rapidly as immunotherapy, targeted drugs, and measurable residual disease (MRD) testing move into routine care. This review summarizes major therapeutic advances reported between 2019 and 2026.
Methods: This SANRA-informed narrative review synthesized peer-reviewed clinical studies, major guidelines and consensus recommendations, and regulatory sources, emphasizing evidence from January 2019 through 15 August 2026 with selective earlier landmark studies. Evidence was summarized descriptively; no formal systematic-review screening, risk-of-bias assessment, GRADE evaluation, or meta-analysis was performed.
Results: In ECOG-ACRIN E1910, adding blinatumomab to consolidation chemotherapy improved 3-year overall survival in adults with MRD-negative remission from 68% to 85% [33]. Preliminary conference-reported phase III GIMEMA ALL2820 results favored ponatinib plus blinatumomab over imatinib plus chemotherapy for complete hematologic remission, day-133 MRD response, and 18-month event-free survival in newly diagnosed Ph+ ALL [69]. CD19-directed CAR T-cell therapies produce high remission rates in R/R B-cell precursor ALL [35, 43, 46], while revumenib provides a targeted option for R/R KMT2A-translocated acute leukemia [22, 56]. MRD increasingly informs risk-adapted treatment decisions [66].
Conclusions: ALL treatment is becoming more personalized and increasingly guided by immunotherapy, molecular targets, and MRD, although resistance, immune toxicity, transplantation decisions, cost, and unequal access remain important barriers.
INTRODUCTION
Cervical cancer remains a significant global health challenge. This narrative review synthesizes evidence from PubMed/MEDLINE, Embase, and ClinicalTrials.gov (January 2010 to August 2026), focusing on randomized prospective trials of systemic combination therapies.
AREAS COVERED
In locally advanced cervi...
Alfonso Dueñas-González, Pamela Pastrana-Peralta, A. Romo-Pérez et al.· Expert Opinion on Pharmacoth...· 0 citations
INTRODUCTION
Acute promyelocytic leukemia (APL) has evolved from one of the most rapidly fatal neoplasms into the most curable acute myeloid leukemia subtype, following the sequential clinical introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Despite cure rates now approaching 100% in non-high-...
A. Laganà, E. Scalzulli, M. Bisegna et al.· Expert Opinion on Pharmacoth...· 0 citations
In Ph-positive ALL, ponatinib has increasingly replaced imatinib as the preferred tyrosine kinase inhibitor in contemporary regimens, while chemotherapy-free ponatinib plus blinatumomab, as evaluated in GIMEMA ALL2820, has emerged as an important therapeutic benchmark.
Matthias Zanker, Eduard Schulz· memo - Magazine of European...· 0 citations
ABSTRACT Importance Relapsed/refractory acute lymphoblastic leukemia (R/R ALL) remains a major challenge in pediatric hematologic malignancies, with poor outcomes following standard salvage therapy. Real‐world data regarding the use of bortezomib‐based regimens in Chinese children are limited. Objective To evaluate the...
Xing-Yu Zhao, Jian Wang, Li-Ping Que et al.· Pediatric Investigation· 0 citations
Acute lymphoblastic leukemia (ALL), the most common childhood cancer, shows >90% survival in high-income settings but poorer outcomes in low- and middle-income regions due to increased infection rates, toxicity, and treatment abandonment. This single-center retrospective study from January 2016 to June 2025, analyzed o...
Surabhi Pokhariyal, Sohini Chakraborty, S. Arora et al.· Leukemia and Lymphoma· 0 citations
Pediatric ALL protocols in Uzbekistan had the lowest overall costs, Kazakhstan included a broader range of targeted therapies with intermediate costs, and Russia had the highest costs.
Umarova Shakhnoz Ziyatovna, Rakhmonova Gulhayo Avazbekovna, Pulatova Nargiza Sirojiddinovna et al.· Iranian Journal of Pediatric...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.